Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy

European Journal of Cancer

Volumn 39, Issue 4, 2003, Pages 438-446

  Aas, T ^a   Geisler, S ^a   Eide, G E ^a   Haugen, D F ^a   Varhaug, J E ^a   Bassoe A M ^a   Thorsen, T ^a   Berntsen, H ^a   Borresen Dale A L ^b   Akslen, L A ^c   Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptotic factors; Cell proliferation; Chemotherapy resistance; Locally advanced breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS RATE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MITOSIS; MUTATION; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12244252332     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00732-3     Document Type: Article

References (53)

1. Shackney S.E., McGormack G.W., Cuchural G.J. Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy. an analytical review Ann. Intern. Med. 89:1978;107-121.
2. Skipper H.E., Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res. 30:1970;1883-1897.
3. Thor A.D., Berry D.A., Budman D.R.et al. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 90:1998;1346-1360.
4. Paik S.M., Bryant J., Park C.H.et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptore-negative breast cancer. J. Natl. Cancer Inst. 90:1998;1361-1370.
5. Lowe S., Earl Ruley H., Jacks T., Housman D.E. P53-dependent apoptosis modulates the cytotoxicity of anticancer agent. Cell. 74:1993;957-967.
6. Lowe S.W., Bodis S., McClatchey A.et al. p53 status and efficacy of cancer therapy in vitro. Science. 266:1994;807-810.
7. Wattel E., Preudhomme C., Hecquet B.et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:1994;3148-3157.
8. Preudhomme C., Dervite I., Wattel E.et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukaemia. e report of 48 cases J. Clin. Oncol. 13:1995;812-820.
9. Ichikawa A., Kinoshita T., Watanabe T.et al. Mutations of the p53 gene as a prognostic factor in aggressiva B-cell lymphoma. N. Engl. J. Med. 337:1997;529-534.
10. Aas T., Børresen A.-L., Geisler S.et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2:1996;811-814.
11. Geisler S., Lønning P.E., Aas T.et al. Influence of TP53 gene alterations and c-erB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2001;2505-2512.
12. Aas T., Geisler S., Paulsen T.et al. Primary systemic therapy with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol. 35(Suppl. 5):1996;5-8.
13. Hayward J.L., Rubens R.D., Carbone P.P., Heuson J.C., Kumaoka S., Segaloff A. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer. 35:1977;292-298.
14. Lønning PE. Studying chemoresistance in vivo; lessons from breast cancer. Lancet Oncol, in press.
15. Elston C.W., Ellis I.O. Patological prognostic factors in breast cancer. The value of histological grade in breast cancer experience from a long-term follow-up. Histopathology. 19:1991;403-410.
16. Thorsen T. Occupied and unoccupied nuclear oestradiol receptor in human breast tumors. relation to oestradiol and progesterone cytosol receptors J. Steroid. Biochem. 10:1979;661-668.
17. Gasparini G., Pozza F., Meli S., Reitano M., Santini G., Bevilacqua P. Breast cancer cell kinetics. determination of growth Fractions by monoclonal antibody Ki67 and correlation with flow cytometric s-phase and with some features of tumour aggressiveness Anticancer Res. 11:1990;2015-2022.
18. Salvesen H., Iversen O.E., Akslen L.A. Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression. a population-based endometrial carcinoma study J. Clin. Oncol. 17:1999;1382-1390.
19. Andersen T.I., Børresen A.-L. Alterations of the TP-53 gene as a potential prognostic markers in breast carcinomas. Diagn. Mol. Pathol. 4:1995;203-211.
20. Børresen-Dale A.-L., Lystad S., Langerød A. Temporal temperature gradient gel electrophoresis using the Dcode system. Bio. Rad. Bull. 99:1997;12-13.
21. Spearman C. The proof and measurement of association between two things. Am. J. Psychol. 15:1904;72-101.
22. Fisher R.A. The Design of Experiments. [7th edn, 1960]:1935;Oliver & Boyd, Edinburgh/London.
23. Mann H.B., Whitney D.R. On a test of whether one of two variables is statistically larger than the other. Ann. Math. Stat. 18:1947;50-60.
24. Cox D.R. The Analysis of Binary Data. 1970;Methuen, London.
25. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;113-170.
27. Cox D.R. Regression models and life tables [with discussion]. J. Royal Stat. Soc., Series B. 34:1972;187-220.
28. van Slooten H.J., van de Vijver M.J., Børresen A.L.et al. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J. Pathol. 189:1999;504-513.
29. Allred D.C., Clark G.M., Elledge R.et al. Association of the p-53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 3:1993;200-206.
30. Zhang G.J., Kimijima I., Abe R.et al. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in breast cancers. Anticancer Res. 18:1998;1989-1998.
31. Yang Q., Sakurai T., Jing X.et al. Expression of Bcl-2, but not Bax, proliferates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol. Int. 49:1999;775-780.
32. Bottini A., Berruti A., Bersiga A.et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 6:2000;2751-2758.
33. Smith M.L., Fornace A.J. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol. 7:1995;69-75.
34. Smith M.L., Chen I.T., Zhan Q.et al. Interaction of the p-53 regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 266:1994;1376-1380.
35. Amadori D., Volpi A., Maltoni R.et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer. a prospective study Breast Cancer Res. Treat. 43:1997;7-14.
36. Collecchi P., Baldini E., Giannessi P.et al. Primary Chemotherapy in locally advanced breast cancer (LABC). effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers Eur. J. Cancer. 34:1998;1701-1704.
37. Colleoni M., Orvieto E., Nole F.et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur. J. Cancer. 35:1999;574-579.
38. Daidone M.G., Silvestrini R., Luisi A.et al. Changes in biological markers after primary chemotherapy for breast cancer. Int. J. Cancer. 61:1995;301-305.
39. Bottini A., Berruti A., Bersiga A.et al. Effect of neoadjuvant chemotherapy on Ki-67 labeling index, e-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res. 16:1996;3105-3110.
40. Linn S.C., Pinedo H.M., van Ark-Otte J.et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer. 71:1997;787-795.
41. Frassoldati A., Adami F., Banzi C., Criscuolo M., Piccini L., Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res. Treat. 44:1997;185-192.
42. Chang J., Powles T.J., Allred D.C.et al. Biological markers as predictors of clinical outcome from systemic therapy for operable breast cancer. J. Clin. Oncol. 17:1999;3058-3063.
43. Billgren A.M., Rutqvist L.E., Tani E., Wilking N., Fornander T., Skoog L. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol. 38:1999;597-601.
44. Daidone M., Veneroni S., Benini E.et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int. J. Cancer (Pred. Oncol.). 84:1999;580-586.
45. Bonetti A., Zaninelli M., Rodella S.et al. Tumour proliferative activity and response to first line chemotherapy in advanced breast cancer. Breast Cancer Res. Treat. 38:1996;289-297.
46. Niskanen E., Blomquist C., Franssila K., Hietanen P., Wasenius V.M. Predictive value of c-erB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer. 76:1997;917-922.
47. Muss H.B., Thor A.D., Berry D.A.et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer. N. Engl. J. Med. 330:1994;1260-1266.
48. Ellis P., Smith I., Ashley S.et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16:1998;107-114.
49. Binder C., Marx D., Overhoff R., Binder L., Schauer A., Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann. Oncol. 6:1995;1005-1010.
50. Berardo M.D., Elledge R.M., de Moor C., Clark G.M., Osborne C.K., Allred D.C. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 82:1998;1296-1302.
51. Vakkala M., Lahteenmaki K., Raunio H., Paakko P., Soini Y. Apoptosis during breast carcinoma progression. Clin. Cancer Res. 5:1999;319-324.
52. Minckwitz G., Costa S.D., Raab G.et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast. a randomized, controlled, open phase IIb study J. Clin. Oncol. 19:2001;3506-3515.
53. Kuerer H.M., Newman L.A., Smith T.L.et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17:1999;460-469.